Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005)

Journal of Clinical Oncology

Volumn 26, Issue 21, 2008, Pages 3511-3516

  Corsini, Michele M ^a   Miller, Robert C ^a   Haddock, Michael G ^a   Donohue, John H ^a   Farnell, Michael B ^a   Nagorney, David M ^a   Jatoi, Aminah ^a   McWilliams, Robert R ^a   Kim, George P ^a   Bhatia, Sumita ^a   Iott, Matthew J ^a   Gunderson, Leonard L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS CARCINOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES;

EID: 49049097154     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.8782     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg 237:74-85, 2003
3. Trede M, Schwall G, Saeger HD: Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 211:447-458, 1990
4. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68-72, 1993
5. Crist DW, Sitzmann JV, Cameron JL: Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 206:358-365, 1987
6. Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985
7. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782, 1999
8. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004
9. Greene FL, Page DL, Fleming ID, et al (eds): AJCC cancer staging manual (ed 6). New York, NY, Springer-Verlag, 2002
10. Gunderson LL, Martenson JA, Smalley SR, et al: Upper gastrointestinal cancers: Rationale, results, and techniques of treatment. Front Radiat Ther Oncol 28:121-139, 1994
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
13. Garofalo MC, Regine WF, Tan MT: On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 244:332-333, 2006
14. Yeo CJ, Abrams RA, Grochow LB, et al: Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225:621-633, 1997
15. Greco JA, Castaldo ET, Feurer ID, et al: Survival benefit with adjuvant radiation therapy in surgically resected pancreatic cancer. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 19-21, 2007, Orlando, FL
16. Swartz MJ, Abrams RA, Winter J, et al: Adjuvant chemoradiation for adenocarcinoma of the pancreas: The Johns Hopkins experience. Int J Radiat Oncol Biol Phys 66:582, 2006 (suppl)
17. Corsini MM, Miller RC, Haddock MG, et al: Adjuvant radiation and chemotherapy for pancreatic adenocarcinoma: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 69:S79, 2007 (suppl; abstr)
18. Bhatia S, Miller RC, Haddock MG, et al: Adjuvant therapy for ampullary carcinomas: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 66:514-519, 2006
19. Garofalo M, Flannery T, Regine W: The case for adjuvant chemoradiation for pancreatic cancer. Best Pract Res Clin Gastroenterol 20:403-416, 2006
20. Stocken DD, Buchler MW, Dervenis C, et al: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92:1372-1381, 2005
21. Bergenfeldt M, Albertsson M: Current state of adjuvant therapy in resected pancreatic adenocarcinoma. Acta Oncol 45:124-135, 2006
22. Choti MA: Adjuvant therapy for pancreatic cancer: The debate continues. N Engl J Med 350:1249-1251, 2004
23. Chu QD, Khushalani N, Javle MM, et al: Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas? Ann Surg Oncol 10:539-545, 2003
24. DiMagno EP, Reber HA, Tempero MA: American Gastroenterological Association. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117:1464-1484, 1999
25. Winter JM, Cameron JL, Campbell KA, et al: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 10:1199-1210, 2006
26. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007
27. Regine WF, Winter KW, Abrams R, et al: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 24:180S, 2006 (suppl; abstr 4007)
28. Poplin E, Levy DE, Berlin J, et al: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24:180S, 2006 (suppl; abstr LBA4004)
29. Kindler HL, Niedzwiecki D, Hollis D, et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25:199S, 2007 (suppl; abstr 4508)
30. Philip PA, Benedetti J, Fenoglio-Preiser C, et al: Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (Pca): SWOG S0205 study. J Clin Oncol 25:199S, 2007 (suppl; abstr LBA4509)